ProMIS Neurosciences Phase 1b data show zero ARIA and p-tau217 reduction
Interim Phase 1b Alzheimer’s trial data for a novel antibody platform targeting misfolded proteins report zero ARIA cases and a significant p-tau217 reduction. Top-line results are expected in Q1 2027.
ProMIS Neurosciences said its novel antibody platform targeting misfolded proteins in neurodegenerative diseases showed strong interim safety and promising biomarker signals in a Phase 1b Alzheimer’s trial. The company reported zero ARIA cases and significant p-tau217 reduction. Top-line results are expected in Q1 2027.